The other option in peptic ulcer therapy

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Histamine H2-antagonists are the standard for peptic ulcer disease (PUD) treatment.
• Other agents, including antacids, demonstrate comparable ulcer healing rates.
• Sucralfate presents a well-documented therapeutic option for PUD.

Purpose of the Study:

• To evaluate sucralfate's efficacy in treating peptic ulcer disease.
• To compare sucralfate's healing rates with histamine H2-antagonists and placebo.
• To explore sucralfate's potential in maintenance therapy and reflux esophagitis.

Main Methods:

• Sucralfate, a sucrose octosulfate salt, acts as a coating agent.
• It binds to ulcer sites, protecting against acid-pepsin.
• Minimal absorption suggests low potential for drug interactions.

Main Results:

• Sucralfate demonstrated superiority over placebo in short-term duodenal and gastric ulcer healing.
• Healing rates with sucralfate were comparable to cimetidine.
• Evidence supports sucralfate's role in preventing duodenal ulcer recurrence.

Conclusions:

• Sucralfate is an effective treatment for peptic ulcers, with healing rates similar to cimetidine.
• Its mechanism involves local coating and cytoprotection, with minimal systemic absorption.
• Sucralfate shows promise for maintenance therapy and potentially reflux esophagitis.